Literature DB >> 32333167

Levodopa challenge test: indications, protocol, and guide.

Gerard Saranza1, Anthony E Lang2,3,4.   

Abstract

A drug challenge test in Parkinson's disease, such as the levodopa challenge test (LCT), is an easy and generally safe procedure, which has been used by clinicians for various indications. The results of the test have significant implications in the management of patients, from preoperative evaluation for deep brain stimulation to providing the basis for medication adjustments to address motor or non-motor fluctuations and dyskinesias. This paper reviews the different indications and protocols commonly used in an acute LCT. Potential complications of the procedure and an overview of levodopa responsiveness and unresponsiveness are also discussed.

Entities:  

Keywords:  DBS screening; Levodopa challenge test; Levodopa responsiveness; Levodopa unresponsiveness; Parkinson's disease; Short-duration response

Year:  2020        PMID: 32333167     DOI: 10.1007/s00415-020-09810-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  12 in total

1.  Upper brainstem GABA levels in Parkinson's disease.

Authors:  Yulu Song; Tao Gong; Muhammad G Saleh; Mark Mikkelsen; Guangbin Wang; Richard A E Edden
Journal:  MAGMA       Date:  2021-03-20       Impact factor: 2.310

Review 2.  Preoperative Levodopa Response and Deep Brain Stimulation Effects on Motor Outcomes in Parkinson's Disease: A Systematic Review.

Authors:  Zhengyu Lin; Chencheng Zhang; Dianyou Li; Bomin Sun
Journal:  Mov Disord Clin Pract       Date:  2021-12-09

Review 3.  High-dose versus low-dose inhaled levodopa (CVT-301) in patients with Parkinson disease for the treatment of OFF episodes: a meta-analysis of randomized controlled trials.

Authors:  Zeya Yan; Wei Wang; Xinyu Tao; Wei Cheng; Gang Zuo; Zhouqing Chen; Zhong Wang; Gang Chen
Journal:  Neurol Sci       Date:  2022-07-30       Impact factor: 3.830

4.  Levodopa responsiveness in Parkinson's disease: harnessing real-life experience with machine-learning analysis.

Authors:  Ruth Djaldetti; Ben Hadad; Johnathan Reiner; Bella Askenazi Kharash; Boaz Lerner
Journal:  J Neural Transm (Vienna)       Date:  2022-08-27       Impact factor: 3.850

5.  Pre-operative cognitive burden as predictor of motor outcome following bilateral subthalamic nucleus deep brain stimulation in Parkinson's disease.

Authors:  Venus Tang; Xian Lun Zhu; Claire Lau; Anne Chan; Karen Ma; Jonas Yeung; Tom Cheung; Jill Abrigo; David Yuen Chung Chan; Danny Chan; Vincent Mok; Wai Sang Poon
Journal:  Neurol Sci       Date:  2022-09-01       Impact factor: 3.830

6.  Optimizing the selection of Parkinson's disease patients for neuromodulation using the levodopa challenge test.

Authors:  Dinkar Kulshreshtha; Marcus Pieterman; Greydon Gilmore; Mandar Jog
Journal:  J Neurol       Date:  2021-06-30       Impact factor: 6.682

Review 7.  Deep Brain Stimulation Selection Criteria for Parkinson's Disease: Time to Go beyond CAPSIT-PD.

Authors:  Carlo Alberto Artusi; Leonardo Lopiano; Francesca Morgante
Journal:  J Clin Med       Date:  2020-12-04       Impact factor: 4.241

8.  Does Subthalamic Deep Brain Stimulation Impact Asymmetry and Dyscoordination of Gait in Parkinson's Disease?

Authors:  Deepak K Ravi; Christian R Baumann; Elena Bernasconi; Michelle Gwerder; Niklas K Ignasiak; Mechtild Uhl; Lennart Stieglitz; William R Taylor; Navrag B Singh
Journal:  Neurorehabil Neural Repair       Date:  2021-09-22       Impact factor: 3.919

9.  Serum Folate, Vitamin B12 Levels, and Systemic Immune-Inflammation Index Correlate With Motor Performance in Parkinson's Disease: A Cross-Sectional Study.

Authors:  Siying Li; Qingxi Zhang; Yuyuan Gao; Kun Nie; Yanling Liang; Yuhu Zhang; Lijuan Wang
Journal:  Front Neurol       Date:  2021-05-21       Impact factor: 4.003

10.  Effect of Acute Levodopa Up-Titration on Blood Pressure in Patients With Early Stage Parkinson's Disease: Results of a Levodopa Challenge Test.

Authors:  Xiaoqin He; Chengjun Mo; Yi Zhang; Ying Cai; Xiaodong Yang; Yiwei Qian; Qin Xiao
Journal:  Front Aging Neurosci       Date:  2022-01-03       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.